代謝相關(guān)脂肪性肝病既往稱(chēng)為非酒精性脂肪肝，與肥胖、糖尿病、高脂血癥等關(guān)系密切，還明顯增加心血管死亡的風(fēng)險(xiǎn)。大黃素是大黃、何首烏中主要的活性成分，具有多種生物學(xué)功能。大黃素可通過(guò)降低肝細(xì)胞脂質(zhì)沉積、抑制肝臟炎癥反應(yīng)、抗胰島素抵抗、抑制肝纖維化、抗氧化應(yīng)激反應(yīng)等多種途徑對(duì)代謝相關(guān)脂肪性肝病發(fā)揮治療作用?？偨Y(jié)了大黃素治療代謝相關(guān)脂肪性肝病的作用機(jī)制，為代謝相關(guān)脂肪性肝病的治療提供參考。

Metabolic associated fatty liver disease (MAFLD), formerly known as non-alcoholic fatty liver disease, is closely related to obesity, diabetes, hyperlipidemia, etc., and also significantly increases the risk of cardiovascular death. Emodin is the main active ingredient in Rhei Radix et Rhizoma and Polygoni Multiflori Radix, and has a variety of biological functions. Emodin plays a therapeutic effects on MAFLD in multiple ways and multiple targets, such as reducing lipid deposition in liver cells, inhibiting hepatic inflammatory response, anti-insulin resistance, inhibiting liver fibrosis, and anti-oxidative stress response, etc. This paper discusses the mechanism of action of emodin in treatment of MAFLD, and provides a reference for the treatment of MAFLD.

R977

重慶市科衛(wèi)聯(lián)合醫(yī)學(xué)科研項(xiàng)目(2018MSXM089)